Terry ChrisomalisInvesting Group Leader
Summary
- Eli Lilly and Company delivered a monumental Q2 2026, with revenues up 48% to $23 billion, driven by MOUNJARO and ZEPBOUND.
- I maintain a ‘Strong Buy’ rating on the company, citing robust double-digit growth in key drugs and successful pipeline expansion, including positive phase 3 retatrutide data.
- EBGLYSS achieved 131% YoY sales growth and secured a label expansion, offering the only 6-dose annual maintenance regimen for moderate-to-severe AD.
- LLY raised 2026 revenue guidance to $85–$87 billion, strengthened by market share gains in U.S. incretin analogs and continued pipeline momentum.
- Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »
The last time I spoke about Eli Lilly and Company (LLY), it was in a Seeking Alpha article entitled “Eli Lilly: ‘Strong Buy’ Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions
Terry Chrisomalis
Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from <a href="https://healthylife7.com/nurse-camp-inspires-central-iowa-students-to-explore-<a href="https://healthylife7.com/state-nearly-achieved-universal-healthcare-now-millions-are-losing-it/” title=”State nearly achieved universal healthcare. Now, millions are losing it”>healthcare-careers/” title=”Nurse Camp inspires central Iowa students to explore healthcare careers”>Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
